Morgan Stanley Palatin Technologies Inc Transaction History

Morgan Stanley

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Oct 27, 2022	SELL	$0.27 - $0.5 $2,829 - $5,240	-10,481 Reduced 10.29%	91,405 $26,000
Q2 2022 Aug 15, 2022	SELL	$0.27 - $0.5 $2,829 - $5,240	-10,481 Reduced 10.29%	91,405 $26,000
Q1 2022 Oct 27, 2022	BUY	$0.37 - $0.54 $3,877 - $5,659	10,481 Added 11.47%	101,886 $47,000
Q1 2022 May 13, 2022	SELL	$0.37 - $0.54 $3 - $5	-10 Reduced 0.01%	101,886 $47,000
Q4 2021 Feb 14, 2022	SELL	$0.34 - $0.86 $16,885 - $42,709	-49,662 Reduced 32.77%	101,896 $51,000
Q3 2021 Nov 15, 2021	BUY	$0.44 - $0.63 $66,685 - $95,481	151,558 New	151,558 $68,000

2.94K

Ticker PTN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,290,480
Market Cap $8.83M
Description
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing o...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.